Abstract: 
The crucial significance of nanomaterials-based nanostructures has ushered in a new era of nanomedicine. Nanoparticles have evolved into the primary catalyst for the modification of numerous traditional materials’ properties due to their smaller size and larger surface area, which causes them to be more reactive to other molecules. Nanoparticles have better biocompatibility and biodegradability, as well as the ability to modify surfaces. Nanomedicine has opened up a new therapeutic route for combating viral infections and improving treatment outcomes. Antiviral release kinetics could be altered, increasing bioavailability, improving efficacy, limiting adverse drug side effects, and lowering treatment costs with nanoparticulate-based devices. They may also allow antiviral medications to be delivered to specific target locations and viral reservoirs in the body. These appearances are most common in viral infections, where more treatment doses are required; pharmaceuticals are expensive, and therapeutic success is dependent on a patient’s compliance with the administration protocol. This review discusses the current state of nanoparticulate delivery systems in antiviral therapy, as well as its definition and description, as well as certain unique characteristics. The report concludes with a review of the various hurdles that must be overcome before nanotechnology may be used to develop safe and effective antiviral compositions for clinical use.

Keywords: Nanoparticles, Herpes Viruses, Antivirals, Solubility, Bioavailability.